Indian Immunologicals Limited

The National Dairy Development Board (NDDB) set up Indian Immunologicals Ltd. (IIL) in 1982 with the objective of making Foot and Mouth Disease (FMD) vaccine available to farmers at an affordable price. The technology for FMD vaccine manufacture was obtained from M/s. Wellcome Foundation Limited, United Kingdom. The plant in Hyderabad today has a capacity to make 80 million trivalent doses of FMD vaccine. Following the successful introduction of Foot &Mouth Disease Vaccine-Raksha, IIL launched the tissue culture vaccine "Raksharab"​ in 1989. This was the first Indian tissue culture vaccine in the market.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CELL AND GENE THERAPY

MISSION BIO AND S2 GENOMICS TO PROVIDE TUMOR SAMPLE FOR SINGLE-CELL DNA ANALYSIS

Mission Bio | April 20, 2022

news image

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...

Read More

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

news image

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More

INDUSTRIAL IMPACT

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

news image

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

news image

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More
news image

CELL AND GENE THERAPY

MISSION BIO AND S2 GENOMICS TO PROVIDE TUMOR SAMPLE FOR SINGLE-CELL DNA ANALYSIS

Mission Bio | April 20, 2022

Mission Bio, Inc., a leader in high-throughput single-cell DNA and multi-omics analysis, announced today a co-marketing agreement with S2 Genomics, Inc., a leading developer of laboratory automation solutions for processing solid tissues for single-cell applications, to provide a single streamlined workflow for solid tumor applications from sample prep to analysis. Christine A. Iacobuzio-Donahue, MD, Ph.D., Director of the Center for Pancreatic Cancer Research at Memorial Sloan Kettering Cancer ...

Read More
news image

CELL AND GENE THERAPY

NEUROPHTH AND AAVNERGENE ANNOUNCES STRATEGIC AAV CAPSIDS PARTNERSHIP FOR NEXT-GENERATION OPHTHALMIC GENE THERAPY

Neurophth | January 19, 2021

Neurophth Therapeutics, Inc., a subsidiary of Wuhan Neurophth Biotechnology Ltd. gene therapy organization, and AAVnerGene Inc., a practicing AAV innovation organization, reports a strategic partnership to provide Neurophth with overall rights to commonly choose adeno-associated virus (AAV) capsids for the next generation ophthalmic gene therapy. AAVnerGene's Tissue-specific, Highly-transductive and Expressive New AAVs (ATHENA) screening stage can productively choose the best ...

Read More
news image

INDUSTRIAL IMPACT

TRANSPERFECT LIFE SCIENCES AND INNOVADERM RESEARCH EXPAND TRIAL INTERACTIVE PARTNERSHIP

TransPerfect Life Sciences | February 16, 2022

TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, today announced that Innovaderm will scale their implementation of Trial Interactive to further enable and optimize remote clinical operations. Innovaderm, a North America-based contract research organization (CRO) that specializes in clinical studies for dermatology, leveraged Trial Interactive remote monitoring ...

Read More
news image

RESEARCH

POSTERA ANNOUNCES $260M MULTI-TARGET STRATEGIC AI LAB COLLABORATION WITH PFIZER

PostEra | January 12, 2022

PostEra, a biotechnology company specializing in machine learning for preclinical drug discovery, announced the expansion of the company's existing strategic collaboration with Pfizer. The expanded multi-target research program will establish an AI Lab where PostEra and Pfizer jointly advance multiple drug discovery programs with an initial focus in oncology and COVID-19 antiviral therapeutics. The AI Lab will leverage novel machine learning for medicinal chemistry built upon Pfizer's da...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us